nach oben

Erschienen in:

01.02.2016 | Original Article

Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)

verfasst von: Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto, Takako Doi, Kyuichiro Miyara, Hiroki Odagiri, Kaoru Kitamura, Keisuke Ariyoshi, Tempei Miyaji, Hiroto Ishiki, Kenichi Inoue, Chizuko Tsutsumi, Yoshiaki Sagara, Takuhiro Yamaguchi

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power^® (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and l-carnitine, in controlling CRF in breast cancer patients in Japan.

Methods

Breast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events.

Results

Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed.

Conclusion

IP may control moderate-severe CRF in breast cancer patients.

Trial registration

The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.

Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14:151–161

Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef

Gaston-Johansson F, Fall-Dickson JM, Bakos AB, Kennedy MJ (1999) Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract 7:240–247PubMedCrossRef

Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R (1999) Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 79:1479–1486PubMedPubMedCentralCrossRef

Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA (2007) Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110:1851–1859PubMedPubMedCentralCrossRef

Gutstein HB (2001) The biologic basis of fatigue. Cancer 92:1678–1683PubMedCrossRef

Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183PubMedCrossRef

Okuyama T, Akechi T, Kugaya A, Okamura H, Imoto S, Nakano T, Mikami I, Hosaka T, Uchitomi Y (2000) Factors correlated with fatigue in disease-free breast cancer patients: application of the cancer fatigue scale. Support Care Cancer 8:215–222PubMedCrossRef

Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082PubMedCrossRef

10.

Horneber M, Fischer I, Dimeo F, Ruffer JU, Weis J (2012) Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 109:161–171 quiz 172PubMedPubMedCentral

11.

Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A, Silberstein PT, Duane SF, Loprinzi CL (2010) Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central cancer treatment group NCCTG-N05C7 trial. J Clin Oncol 28:3673–3679PubMedPubMedCentralCrossRef

12.

Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manag 38:650–662CrossRef

13.

Auret KA, Schug SA, Bremner AP, Bulsara M (2009) A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manag 37:613–621CrossRef

14.

Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, Peppone L, Hemstad A, Esparaz BT, Hopkins JO (2010) A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116:3513–3520PubMedPubMedCentralCrossRef

15.

Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, Kaptchuk TJ, Eisenberg DM (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135:262–268PubMedCrossRef

16.

Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739PubMedCrossRef

17.

Sood A, Barton DL, Bauer BA, Loprinzi CL (2007) A critical review of complementary therapies for cancer-related fatigue. Integr Cancer Ther 6:8–13PubMedCrossRef

18.

Higashiguchi T, Futamura A, Ito A (2010) Effect of a complementary nutrition diet for improving clinical condition and function in terminal cancer patients: a controlled clinical trial. JJSMN 44:157–169

19.

Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR (2007) Mechanisms of cancer-related fatigue. Oncologist 12(Suppl 1):22–34PubMedCrossRef

20.

Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T, Sugino T, Shirai T, Kajimoto Y, Kuratsune H, Kajimoto O, Watanabe Y (2008) Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 24:293–299PubMedCrossRef

21.

Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessi M, Spiga C, Astara G, Maccio A, Mantovani G (2006) Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22:136–145PubMedCrossRef

22.

Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M (2007) L-carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 86:1738–1744PubMed

23.

Blomstrand E (2006) A role for branched-chain amino acids in reducing central fatigue. J Nutr 136:544s–547sPubMed

24.

Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553PubMedCrossRef

25.

Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 32:1840–1850PubMedPubMedCentralCrossRef

26.

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85:1186–1196PubMedCrossRef

27.

Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manag 25:106–117CrossRef

28.

Johnston M, Pollard B, Hennessey P (2000) Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 48:579–584PubMedCrossRef

29.

Matsudaira T, Igarashi H, Kikuchi H, Kano R, Mitoma H, Ohuchi K, Kitamura T (2009) Factor structure of the hospital anxiety and depression scale in Japanese psychiatric outpatient and student populations. Health Qual Life Outcomes 7:42PubMedPubMedCentralCrossRef

30.

Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, Noguchi Y, Ogasawara H, Yoshida K (1998) A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer (Oxf) 34:810–815CrossRef

31.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osaba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

32.

Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 324:1417PubMedPubMedCentralCrossRef

33.

Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768PubMed

34.

Okamoto T, Shimozuma K, Katsumata N, Koike M, Hisashige A, Tanaka K, Ohsumi S, Saito M, Shikama N, Mitsumori M, Yamauchi C, Watanabe T (2003) Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer (Tokyo) 10:204–213CrossRef

35.

Brown E, Hurlow A, Rahman A, Closs SJ, Bennett MI (2010) Assessment of fatigue after blood transfusion in palliative care patients: a feasibility study. J Palliat Med 13:1327–1330PubMedCrossRef

36.

World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects 2008. http://www.wma.net/en/30publications/10policies/b3/ Accessed: 3 Dec 2014

37.

The Ethical Guidelines for Clinical Research (Ministry of Labor, Health, and Welfare of Japan). http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/rinsyo/dl/shishin.pdf. Accessed: 3 Dec 2014

38.

Ishiki H, Iwase S, Gyoda Y, Kanai Y, Ariyoshi K, Miyaji T, Tahara Y, Kawaguchi T, Chinzei M, Yamaguchi T (2015) Oral nutritional support can shorten the duration of parenteral hydration in end-of-life cancer patients: a randomized controlled trial. Nutr Cancer 67:105–111PubMedCrossRef

39.

Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG, Wake Forest University Community Clinical Oncology Program Research B (2013) A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11:31–42PubMedPubMedCentral

40.

Cruciani RA, Zhang JJ, Manola J, Cella D, Ansari B, Fisch MJ (2012) l-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol 30:3864–3869PubMedPubMedCentralCrossRef

41.

Patient-Reported Outcomes (Society for Clinical Data Management’s Good Clinical Data Management Practices). http://www.scdm.org/ Accessed: 3 Dec

Titel: Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)
verfasst von: Satoru Iwase
Takashi Kawaguchi
Daisuke Yotsumoto
Takako Doi
Kyuichiro Miyara
Hiroki Odagiri
Kaoru Kitamura
Keisuke Ariyoshi
Tempei Miyaji
Hiroto Ishiki
Kenichi Inoue
Chizuko Tsutsumi
Yoshiaki Sagara
Takuhiro Yamaguchi
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2824-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)